Elucid Reports the US FDA’s Approval of PlaqueIQ Image Analysis Software for Cardiovascular Disease Evaluation
Shots:
- The US FDA has granted 510(k) clearance to PlaqueIQ imaging analysis software, enabling diagnosis of cardiovascular disease (CVD)
- PlaqueIQ uses CCTA to generate detailed reports that help physicians visualize plaque at the vessel level. It non-invasively quantifies and characterizes non-calcified plaque, including lipid-rich necrotic core (LRNC), offering insights into high-risk plaques that may lead to heart attacks or strokes, enabling earlier detection before symptoms or major events occur
- Elucid is beta testing PlaqueIQ and expects a limited release in Q4’24. The company in line for non-invasive FFRCT measurement, derived from PlaqueIQ, to assess coronary blockages and ischemia
Ref: Elucid | Image: Elucid
Related News:- Galderma Receives Health Canada’s Approval for Restylane SHAYPE for Chin Augmentation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
